0001209191-23-050305.txt : 20230921 0001209191-23-050305.hdr.sgml : 20230921 20230921171006 ACCESSION NUMBER: 0001209191-23-050305 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230919 FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katabi Maha CENTRAL INDEX KEY: 0001720685 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41799 FILM NUMBER: 231269730 MAIL ADDRESS: STREET 1: SOFINNOVA INVESTMENTS STREET 2: 3000 SAND HILL ROAD, 4-250 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RayzeBio, Inc. CENTRAL INDEX KEY: 0001825367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (619) 937-2754 MAIL ADDRESS: STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-19 0 0001825367 RayzeBio, Inc. RYZB 0001720685 Katabi Maha C/O RAYZEBIO, INC. 5505 MOREHOUSE DRIVE, SUITE 300 SAN DIEGO CA 92121 1 0 0 0 0 Common Stock 2023-09-19 4 C 0 973653 A 973653 I See footnote Common Stock 2023-09-19 4 C 0 973653 A 973653 I See footnote Common Stock 2023-09-19 4 P 0 236111 18.00 A 1209764 I See footnote Common Stock 2023-09-19 4 P 0 236111 18.00 A 1209764 I See footnote Series D Convertible Preferred Stock 2023-09-19 4 C 0 973653 D Common Stock 973653 0 I By Sofinnova Venture Partners X, L.P. Series D Convertible Preferred Stock 2023-09-19 4 C 0 973653 D Common Stock 973653 0 I By Sofinnova Venture Partners XI, L.P. Every 5.141 shares of Series D Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. The shares are held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The shares are held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The shares were purchased in the Issuer's initial public offering. /s/ Jeff Woodley, Attorney-in-fact 2023-09-21